Sativex achieved sustained
improvements in spasticity vs
placebo when used as an adjunct1

Response rates
Image
graph

Up to 71%
of patients
responded
to 4 weeks’
treatment with
Sativex*1–4

The response rates achieved in practice were at least as good as those seen in clinical trials*1–4

Image
graph-mobile
Image
graph-mobile

Learn about the 4-week trial period and GW Pharmaceuticals’
pay-for-responders scheme

Patients who
respond to
Sativex can have
significant
reductions in
spasticity
severity vs
placebo1,2

Symptom
improvement
Image
icons

Sativex achieved sustained improvements in spasticity vs placebo when used as an adjunct to existing treatment1

Mean NRS scores during single-blind and double-blind randomised treatment phases1

Image
graph
Image
graph-mobile

Adding Sativex to existing treatment can improve a wide range of patients’ spasticity-related symptoms4

Spasticity-related symptoms reported as improved from baseline by patients4

Image
graph
Image
graph-mobile

17.0% of patients had improvements in 2 symptoms, and 16.7% had improvements in ≥3 symptoms from baseline (N=1,615)*4

Safety and tolerability
Image
icons

Sativex was
generally
well tolerated,
with comparable
AE rates
to placebo1,2,5–7

The most common AEs are usually mild8

Dizziness and fatigue are the only very common AEs associated with Sativex

 

They normally occur during the first 4 weeks of treatment and resolve in a few days if treatment is continued8

Less than 5% of patients had serious AEs1–3,5–7,9

0–4.8% and 0–2.6% of patients had serious AEs in clinical trials and long-term registries, respectively1–3,5–7,9

Low discontinuation rates1,2,5,6

2.1–6.4% discontinuation rate due to AEs in clinical trials1,2,5,6

 

16.3% of patients discontinued Sativex due to AEs in a registry with a median follow up of
2 years10

AEs associated with Sativex8

MedDRA system organ class
 
Very common (≥1/10) Common (≥1/100 to <1/10)
 
 
Uncommon (≥1/1,000 to <1/100)
 
 
Infections and infestations Pharyngitis
Metabolism and nutrition disorders Anorexia (including appetite decreased), appetite increased
Psychiatric disorders Depression, disorientation, dissociation, euphoric mood Hallucination (unspecified, auditory, visual), illusion, paranoia, suicidal ideation, delusional perception*
Nervous system disorders Dizziness Amnesia, balance disorder, disturbance in attention, dysarthria, dysgeusia, lethargy, memory impairment, somnolence Syncope
Eye disorders Vision blurred
Ear and labyrinth disorders Vertigo
Cardiac disorders Palpitations, tachycardia
Vascular disorders Hypertension
Respiratory, thoracic and mediastinal disorders Throat irritation
Gastrointestinal disorders Constipation, diarrhoea, dry mouth, glossodynia, mouth ulceration, nausea, oral discomfort, oral pain, vomiting Abdominal pain (upper), oral mucosal discolouration,* oral mucosal disorder, oral mucosal exfoliation,* stomatitis, tooth discolouration
General disorders and administration site conditions Fatigue Application site pain, asthenia, feeling abnormal, feeling drunk, malaise Application site irritation
Injury, poisoning and procedural complaints Fall